About CoMMit: Myeloma Trials Innovated
CoMMit, Myeloma Trials Innovated, Inc. is a designated 501(c)3 nonprofit organization pursuing scientific and educational charitable purposes. Donations made to qualified 501(c)(3) organizations are tax-deductible for the donor.
Our Mission
The mission of COMMIT is to reduce the burden of multiple myeloma by aggregating investigators, patients and private entities to develop better therapies through efficient, and patient-centered clinical trials.
What We Do
Despite recent advances in myeloma diagnosis and therapy, there is still a lot to be done. Until myeloma becomes fully preventable or curable with limited, safe, accessible, and affordable therapy, there will be a constant need to find new solutions through clinical trials. Yet only <10% of myeloma patients in the US participate in clinical trials.
At CoMMit, we believe that improving the lives of individuals suffering with myeloma is urgent. We work relentlessly to hear the needs of patients and families and search for innovative solutions. We engage Pharma, other private entities, investigators, and patients to conduct clinical trials that stand out for their boldness, urgency, innovation, and attention to patients’ priorities.
With >400 patients enrolled in myeloma treatment trials across >15 myeloma centers of excellence, we continue to grow year-by-year, and won’t stop until the work is done.
We are a transparent, mission-focused group standing for patient-centered solutions and merit-based leadership. Check our scientific bylaws to learn more about how we operate.
Our Guiding Principles
Patient-Centered Research Questions
Collegial Collaboration
Inter-institutional Mentorship
Merit-Based Leadership
Transparency
Efficiency through simplicity
All To Create Cures For Patients.
Participating Institutions
COMMIT- Myeloma Trials, Innovated- INC collaborates with a diverse network of partners including research institutions, pharmaceutical companies, healthcare organizations, and patient advocacy groups. Together, we work towards the common goal of advancing myeloma research, enhancing patient support, and improving treatment outcomes. Our partners play a crucial role in shaping the future of myeloma care and contributing to our collective efforts in combating this disease.
Who We Are
Our Board of Directors
Scientific Steering CoMMittee Leadership
(2025-2027 Term)
